Julie Zissimopoulos1, Geoffrey F Joyce, Lauren M Scarpati, Dana P Goldman. 1. Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA 90089-3331.Tel: 213-821-7947; Fax: 213-740-3460. E-mail: zissimop@usc.edu.
Abstract
OBJECTIVES: We assessed whether Medicare Part D reduced disparities in access to medication. STUDY DESIGN: Secondary data analysis of a 20% sample of Medicare beneficiaries, using Parts A and B medical claims from 2002 to 2008 and Part D drug claims from 2006 to 2008. METHODS: We analyzed the medication use of Hispanic, black, and white beneficiaries with diabetes before and after reaching the Part D coverage gap, and compared their use with that of race-specific reference groups not exposed to the loss in coverage. Unadjusted difference-in-difference results were validated with multivariate regression models adjusted for demographics, comorbidities, and zip code-level household income used as a proxy for socioeconomic status. RESULTS: The rate at which Hispanics reduced use of diabetes-related medications in the coverage gap was twice as high as whites, while blacks decreased their use of diabetes-related medications by 33% more than whites. The reduction in medication use was correlated with drug price. Hispanics and blacks were more likely than whites to discontinue a therapy after reaching the coverage gap but more likely to resume once coverage restarted. Hispanics without subsidies and living in low-income areas reduced medication use more than similar blacks and whites in the coverage gap. CONCLUSIONS: We found that the Part D coverage gap is particularly disruptive to minorities and those living in low-income areas. The implications of this work suggest that protecting the health of vulnerable groups requires more than premium subsidies. Patient education may be a first step, but more substantive improvements in adherence may require changes in healthcare delivery.
OBJECTIVES: We assessed whether Medicare Part D reduced disparities in access to medication. STUDY DESIGN: Secondary data analysis of a 20% sample of Medicare beneficiaries, using Parts A and B medical claims from 2002 to 2008 and Part D drug claims from 2006 to 2008. METHODS: We analyzed the medication use of Hispanic, black, and white beneficiaries with diabetes before and after reaching the Part D coverage gap, and compared their use with that of race-specific reference groups not exposed to the loss in coverage. Unadjusted difference-in-difference results were validated with multivariate regression models adjusted for demographics, comorbidities, and zip code-level household income used as a proxy for socioeconomic status. RESULTS: The rate at which Hispanics reduced use of diabetes-related medications in the coverage gap was twice as high as whites, while blacks decreased their use of diabetes-related medications by 33% more than whites. The reduction in medication use was correlated with drug price. Hispanics and blacks were more likely than whites to discontinue a therapy after reaching the coverage gap but more likely to resume once coverage restarted. Hispanics without subsidies and living in low-income areas reduced medication use more than similar blacks and whites in the coverage gap. CONCLUSIONS: We found that the Part D coverage gap is particularly disruptive to minorities and those living in low-income areas. The implications of this work suggest that protecting the health of vulnerable groups requires more than premium subsidies. Patient education may be a first step, but more substantive improvements in adherence may require changes in healthcare delivery.
Authors: Amelia M Haviland; Marc N Elliott; Robert Weech-Maldonado; Katrin Hambarsoomian; Nate Orr; Ron D Hays Journal: Med Care Date: 2012-11 Impact factor: 2.983
Authors: Chien-Wen Tseng; Edward F Tierney; Robert B Gerzoff; R Adams Dudley; Beth Waitzfelder; Ronald T Ackermann; Andrew J Karter; John Piette; Jesse C Crosson; Quyen Ngo-Metzger; Richard Chung; Carol M Mangione Journal: Diabetes Care Date: 2007-11-13 Impact factor: 19.112
Authors: Michael Chernew; Teresa B Gibson; Kristina Yu-Isenberg; Michael C Sokol; Allison B Rosen; A Mark Fendrick Journal: J Gen Intern Med Date: 2008-04-29 Impact factor: 5.128
Authors: Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch Journal: JAMA Date: 2004-05-19 Impact factor: 56.272
Authors: Junling Wang; Ya-Chen Tina Shih; Yolanda Qin; Theo Young; Zachary Thomas; Christina A Spivey; David K Solomon; Marie Chisholm-Burns Journal: Am Health Drug Benefits Date: 2015 Jul-Aug
Authors: Eduardo Velasco-Mondragon; Angela Jimenez; Anna G Palladino-Davis; Dawn Davis; Jose A Escamilla-Cejudo Journal: Public Health Rev Date: 2016-12-07